A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 16, 2024

Primary Completion Date

October 13, 2031

Study Completion Date

October 13, 2031

Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
Interventions
BIOLOGICAL

Liso-cel

Specified dose on specified days

DRUG

Idelalisib

Specified dose on specified days

DRUG

Rituximab

Specified dose on specified days

DRUG

Bendamustine

Specified dose on specified days

DRUG

Fludarabine

Specified dose on specified days

DRUG

Cyclophosphamide

Specified dose on specified days

Trial Locations (48)

1090

Local Institution - 0093, Vienna

3000

Local Institution - 0112, Leuven

5020

Local Institution - 0094, Salzburg

5530

Local Institution - 0113, Yvoir

10029

Local Institution - 0121, New York

11794

Stony Brook University, Stony Brook

20162

Local Institution - 0091, Milan

23502

Virginia Oncology Associates, Norfolk

24105

Local Institution - 0083, Kiel

26506

Local Institution - 0068, Morgantown

28034

Local Institution - 0108, Madrid

30322

Local Institution - 0120, Atlanta

31100

Local Institution - 0034, Toulouse

34295

Local Institution - 0036, Montpellier

35033

Local Institution - 0122, Rennes

37007

Local Institution - 0103, Salamanca

39008

Local Institution - 0107, Santander

40138

Local Institution - 0088, Bologna

40207

Local Institution - 0048, Saint Matthews

44106

University Hospitals Cleveland Medical Center, Cleveland

45242

Oncology Hematology Care, Cincinnati

46010

Local Institution - 0106, Valencia

50937

Local Institution - 0082, Cologne

52242

Local Institution - 0058, Iowa City

53792

University Hospital and UW Health Clinics, Madison

55455

Local Institution - 0101, Minneapolis

63100

Local Institution - 0035, Clermont-Ferrand

69008

Local Institution - 0038, Lyon

75013

Local Institution - 0037, Paris

78704

St. David's South Austin Medical Center, Austin

83712

St. Luke's Mountain States Tumor Institute : Boise, Boise

85234

Banner MD Anderson Cancer Center, Gilbert

89081

Local Institution - 0080, Ulm

91010

Local Institution - 0023, Duarte

95817

University of California Davis (UC Davis) Comprehensive Cancer Center, Sacramento

01307

Local Institution - 0084, Dresden

04103

Local Institution - 0081, Leipzig

D-69120

Local Institution - 0079, Heidelberg

1105 AZ

Local Institution - 0114, Amsterdam

9713 GZ

Local Institution - 0117, Groningen

0372

Local Institution - 0073, Oslo

08035

Local Institution - 0104, Barcelona

08908

Local Institution - 0105, L'Hospitalet Del Llobregat

141 86

Local Institution - 0071, Huddinge

NW1 2PG

Local Institution - 0115, London

SE5 9RS

Local Institution - 0109, London

LS9 7TF

Local Institution - 0111, Leeds

0X3 7LE

Local Institution - 0110, Oxford

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

INDUSTRY